Business Description
Corbus Pharmaceuticals Holdings Inc
NAICS : 325414
SIC : 2834
ISIN : US21833P1030
Description
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company'sĀ development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 44.15 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 39.6 | |||||
| 3-Year EPS without NRI Growth Rate | 37.5 | |||||
| 3-Year FCF Growth Rate | 39.9 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.32 | |||||
| 9-Day RSI | 23.63 | |||||
| 14-Day RSI | 27.58 | |||||
| 6-1 Month Momentum % | -58.87 | |||||
| 12-1 Month Momentum % | 217.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.84 | |||||
| Quick Ratio | 13.84 | |||||
| Cash Ratio | 13.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | -109.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -52.81 | |||||
| ROA % | -38.21 | |||||
| ROIC % | -243.19 | |||||
| ROC (Joel Greenblatt) % | -1198.04 | |||||
| ROCE % | -57.4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.06 | |||||
| Price-to-Tangible-Book | 1.06 | |||||
| EV-to-EBIT | -0.04 | |||||
| EV-to-Forward-EBIT | -0.06 | |||||
| EV-to-EBITDA | -0.04 | |||||
| EV-to-Forward-Revenue | 1520.36 | |||||
| EV-to-FCF | -0.05 | |||||
| Price-to-Net-Current-Asset-Value | 1.1 | |||||
| Price-to-Net-Cash | 1.11 | |||||
| Earnings Yield (Greenblatt) % | -2500 | |||||
| FCF Yield % | -23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRBP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
Corbus Pharmaceuticals Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.67 | ||
| Beta | 3.22 | ||
| Volatility % | 349.77 | ||
| 14-Day RSI | 27.58 | ||
| 14-Day ATR ($) | 0.968013 | ||
| 20-Day SMA ($) | 15.5575 | ||
| 12-1 Month Momentum % | 217.64 | ||
| 52-Week Range ($) | 5.3 - 61.9 | ||
| Shares Outstanding (Mil) | 12.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Corbus Pharmaceuticals Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Corbus Pharmaceuticals Holdings Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Corbus Pharmaceuticals Holdings Inc Frequently Asked Questions
What is Corbus Pharmaceuticals Holdings Inc(CRBP)'s stock price today?
The current price of CRBP is $13.25. The 52 week high of CRBP is $61.90 and 52 week low is $5.30.
When is next earnings date of Corbus Pharmaceuticals Holdings Inc(CRBP)?
The next earnings date of Corbus Pharmaceuticals Holdings Inc(CRBP) is 2025-03-12 Est..
Does Corbus Pharmaceuticals Holdings Inc(CRBP) pay dividends? If so, how much?
Corbus Pharmaceuticals Holdings Inc(CRBP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers